Literature DB >> 2784697

Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture.

J Miyauchi1, C A Kelleher, C Wang, S Minkin, E A McCulloch.   

Abstract

We have proposed that the blasts in acute myeloblastic leukemia (AML) are renewal populations maintained by a small subpopulation of stem cells. The balance between self-renewal and differentiation in blast stem cells may be an important attribute contributing to treatment outcome. Cytosine arabinoside (ara-C) is included in most chemotherapeutic regimens for the treatment of AML. When ara-C survival curves are constructed, the drug appears to be more toxic when an assay is used that detects principally self-renewing divisions, compared with a procedure that depends on terminal divisions. AML blasts usually respond in culture to myelopoietic growth factors; their response often includes a change in self-renewal, differentiation, or both. These features of the model for AML blasts led to the prediction that growth factors would alter ara-C survival curves in a way that depended on the effects of the culture conditions on self-renewal and differentiation. Four AML blast populations were chosen to test this prediction on the basis of our ability to manipulate them by adding or withholding one or more growth factors. Highly significant changes were seen in the ara-C survival curves, depending on the growth factors present in the cultures as was predicted by the observed effects of the factors on renewal and differentiation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784697

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

Review 1.  The role of colony-stimulating factors in acute leukemia.

Authors:  F Herrmann; E Vellenga
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  Autonomous expression of RTVL-H endogenous retroviruslike elements in human cells.

Authors:  D A Wilkinson; J D Freeman; N L Goodchild; C A Kelleher; D L Mager
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

3.  Granulocyte colony-stimulating factor combined regimen in cord blood transplantation for acute myeloid leukemia: a nationwide retrospective analysis in Japan.

Authors:  Takaaki Konuma; Jun Ooi; Naoyuki Uchida; Hiroyasu Ogawa; Kazuteru Ohashi; Heiwa Kanamori; Nobuyuki Aotsuka; Yasushi Onishi; Hiroki Yamaguchi; Yasuji Kozai; Tokiko Nagamura-Inoue; Koji Kato; Ritsuro Suzuki; Yoshiko Atsuta; Seiko Kato; Shigetaka Asano; Satoshi Takahashi
Journal:  Haematologica       Date:  2014-09-12       Impact factor: 9.941

4.  Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study.

Authors:  Sergio Amadori; Stefan Suciu; Ulrich Jehn; Roberto Stasi; Xavier Thomas; Jean-Pierre Marie; Petra Muus; Francois Lefrère; Zwi Berneman; George Fillet; Claudio Denzlinger; Roel Willemze; Pietro Leoni; Giuseppe Leone; Marco Casini; Francesco Ricciuti; Marco Vignetti; Filip Beeldens; Franco Mandelli; Theo De Witte
Journal:  Blood       Date:  2005-03-10       Impact factor: 22.113

Review 5.  Modeling normal and malignant human hematopoiesis in vivo through newborn NSG xenotransplantation.

Authors:  Fumihiko Ishikawa
Journal:  Int J Hematol       Date:  2013-11-21       Impact factor: 2.490

6.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Authors:  Bruno Nervi; Pablo Ramirez; Michael P Rettig; Geoffrey L Uy; Matthew S Holt; Julie K Ritchey; Julie L Prior; David Piwnica-Worms; Gary Bridger; Timothy J Ley; John F DiPersio
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

7.  Challenges in treating older patients with acute myeloid leukemia.

Authors:  Lagadinou D Eleni; Zoumbos C Nicholas; Spyridonidis Alexandros
Journal:  J Oncol       Date:  2010-06-10       Impact factor: 4.375

8.  Inhibition of the self-renewal capacity of blast progenitors from acute myeloblastic leukemia patients by site-selective 8-chloroadenosine 3',5'-cyclic monophosphate.

Authors:  A Pinto; D Aldinucci; V Gattei; V Zagonel; G Tortora; A Budillon; Y S Cho-Chung
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

9.  In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity.

Authors:  N Van der Lely; T De Witte; J Wessels; R Raymakers; P Muus; F Preijers
Journal:  Ann Hematol       Date:  1994-05       Impact factor: 3.673

10.  Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission.

Authors:  Tetsuya Eto; Ken Takase; Toshihiro Miyamoto; Yuju Ohno; Tomohiko Kamimura; Koji Nagafuji; Yasushi Takamatsu; Takanori Teshima; Hisashi Gondo; Shuichi Taniguchi; Koichi Akashi; Mine Harada
Journal:  Int J Hematol       Date:  2013-06-11       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.